Literature DB >> 31569988

Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality.

Jeffrey A Lieberman1, Scott A Small1, Ragy R Girgis1.   

Abstract

Scientific progress in understanding human disease can be measured by the effectiveness of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms and prevent their recurrence in schizophrenia, but the outcomes of most patients historically have been suboptimal. However, a series of findings in studies of first-episode schizophrenia patients transformed the psychiatric field's thinking about the pathophysiology, course, and potential for disease-modifying effects of treatment. These include the relationship between the duration of untreated psychotic symptoms and outcome; the superior responses of first-episode patients to antipsychotics compared with patients with chronic illness, and the reduction in brain gray matter volume over the course of the illness. Studies of the effectiveness of early detection and intervention models of care have provided encouraging but inconclusive results in limiting the morbidity and modifying the course of illness. Nevertheless, first-episode psychosis studies have established an evidentiary basis for considering a team-based, coordinated specialty approach as the standard of care for treating early psychosis, which has led to their global proliferation. In contrast, while clinical high-risk research has developed an evidence-based care model for decreasing the burden of attenuated symptoms, no treatment has been shown to reduce risk or prevent the transition to syndromal psychosis. Moreover, the current diagnostic criteria for clinical high risk lack adequate specificity for clinical application. What limits our ability to realize the potential of early detection and intervention models of care are the lack of sensitive and specific diagnostic criteria for pre-syndromal schizophrenia, validated biomarkers, and proven therapeutic strategies. Future research requires methodologically rigorous studies in large patient samples, across multiple sites, that ideally are guided by scientifically credible pathophysiological theories for which there is compelling evidence. These caveats notwithstanding, we can reasonably expect future studies to build on the research of the past four decades to advance our knowledge and enable this game-changing model of care to become a reality.

Entities:  

Keywords:  Biomarkers; Early Detection; Prevention; Psychosis; Schizophrenia; Treatment

Year:  2019        PMID: 31569988     DOI: 10.1176/appi.ajp.2019.19080865

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  26 in total

1.  Reconsidering brain tissue changes as a mechanistic focus for early intervention in psychiatry.

Authors:  Lena Palaniyappan; Niron Sukumar
Journal:  J Psychiatry Neurosci       Date:  2020-11       Impact factor: 6.186

Review 2.  A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk.

Authors:  Valerie J Sydnor; David R Roalf
Journal:  Schizophr Res       Date:  2020-07-25       Impact factor: 4.939

3.  Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.

Authors:  Ying Peng; Dong Xu; Yuedi Ding; Xingqin Zhou
Journal:  Psychopharmacology (Berl)       Date:  2022-03-16       Impact factor: 4.530

4.  Eye movement indices as predictors of conversion to psychosis in individuals at clinical high risk.

Authors:  Lihua Xu; Dan Zhang; Yuou Xie; Xiaochen Tang; Yegang Hu; Xu Liu; Guisen Wu; Zhenying Qian; Yingying Tang; Zhi Liu; Tao Chen; HaiChun Liu; Tianhong Zhang; Jijun Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-20       Impact factor: 5.760

5.  Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis.

Authors:  Mikaïl Nourredine; Adrien Gering; Pierre Fourneret; Benjamin Rolland; Bruno Falissard; Michel Cucherat; Marie-Maude Geoffray; Lucie Jurek
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

6.  Peripubertal mGluR2/3 Agonist Treatment Prevents Hippocampal Dysfunction and Dopamine System Hyperactivity in Adulthood in MAM Model of Schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306

7.  Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Takahiro Tateno; Suguru Nakajima; Daiki Sasabayashi; Shimako Nishiyama; Yuko Mizukami; Tsutomu Takahashi; Michio Suzuki
Journal:  J Pers Med       Date:  2021-04-21

Review 8.  Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.

Authors:  Susan F Sonnenschein; A Grace
Journal:  Expert Opin Ther Targets       Date:  2020-11-26       Impact factor: 6.902

9.  Temporal and time-frequency features of auditory oddball response in distinct subtypes of patients at clinical high risk for psychosis.

Authors:  GuiSen Wu; XiaoChen Tang; RanPiao Gan; JiaHui Zeng; YeGang Hu; LiHua Xu; YanYan Wei; YingYing Tang; Tao Chen; ChunBo Li; JiJun Wang; TianHong Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-01       Impact factor: 5.270

10.  Reduced Cell-Free Mitochondrial DNA Levels Were Induced by Antipsychotics Treatment in First-Episode Patients With Schizophrenia.

Authors:  Houxian Ouyang; Minfang Huang; Yongming Xu; Qin Yao; Xiangping Wu; Dongsheng Zhou
Journal:  Front Psychiatry       Date:  2021-07-07       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.